PD-L1 IHC 22C3 pharmDx - P150013/S016 wins USFDA approval

The lab test used by doctors for checking the protein programmed cell death ligand 1 (PD-L1) in tumor tissue obtained from patients, who have esophageal squamous cell cancer is done by PD-L1 IHC 22C3 pharmDx. This test has recently got the approval from the USFDA.

The small piece of cancerous tissue from the patient is sent to a lab. The lab then puts the cancerous tissue into wax and cuts a thin slice of it. And then, it is treated with the test slice. If the slice has PD-L1, it will stain dark brown. The pathologist looks at the slice. The lab tells the doctor whether PD-L1 was present in the slice or not. It will help in the determination of the sample positivity based on criteria that are specific for each cancer type.

PD-L1 IHC 22C3 pharmDx can be used by doctors to help in evaluating whether a patient is eligible for treatment with KEYTRUDA®.

There are no known contraindications linked with this testing.